Polyrizon Ltd. (PLRZ) Stock Price & Analysis
Polyrizon Ltd. (PLRZ) closed at USD 8.73 on Friday, October 23, 2026, up 0.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.72; the Oct 23, 2026 session ranged USD 8.73–9.37 on volume of 14,049 shares. Market capitalization is $21.19M, with a 52-week range of USD 2.88–18.2 (NCM). Source: Nexqual, retrieved October 24, 2026 at 07:41 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PLRZ.md
Key facts (PLRZ)
- Analysts: None.
- Total return with dividends: 1Y +35.9% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.
Analysts (PLRZ)
Consensus None.
Total return (dividends reinvested) (PLRZ)
| 1Y (from 2025-10-24) | 5Y (from 2024-10-28) | |
|---|---|---|
| Total return | +35.9% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +36.0% | -93.1% |
| Volatility (annualized) | 156.4% | 341.8% |
| Max drawdown | -52.1% (Oct 2025→Nov 2025) | -99.9% (Dec 2024→Nov 2025) |
PLRZ suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | SciSparc Ltd. (SPRC) | “August 13, 2024, we entered into an exclusive patent license agreement, or the SciSparc License Agreement, with SciSparc Ltd., or SciSparc,” |
| Partner | NV Gold Corp (NVGLF) | “On October 24, 2025, we entered into a subscription agreement with Taurus” |
| Partner | PharmaSeed | “The studies have been conducted mainly by our service partner PharmaSeed Ltd., Israel's” |
| Partner | Clearmind Medicine Inc. (CMND) | “Company has entered into a development agreement with Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind"), a clinical stage” |
| Partner | Medigus | “February 4, 2023, we entered into a convertible loan agreement with Medigus Ltd. (which subsequently changed its name to Xylo Technologies” |
| Partner | Xylo Technologies | “February 4, 2023, we entered into a convertible loan agreement with Medigus Ltd. (which subsequently changed its name to Xylo Technologies” |
| Partner | Reuven Srugo Construction Company | “February 4, 2023, we entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., or Reuven Construction, pursuant” |
| Partner | QUANTUM X LABS INC. (QXL) | “December 15, 2025, Viewbix entered into a securities exchange agreement with Quantum X Labs Ltd. or Quantum, pursuant to which Viewbix” |
Quoted from the company's 20-F filed Mar 25, 2026.
Companies that name PLRZ in their SEC reports
| Relationship to PLRZ | Company | Filing | Sentence |
|---|---|---|---|
| partner | SciSparc Ltd. (SPRC) | 20-F Apr 29, 2026 | “In addition, in August 2024, we entered into an exclusive patent license agreement with Polyrizon Ltd.,” |
PLRZ analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 07:41 UTC)
| Price | USD 8.73 |
|---|---|
| Change | ▲ 0.05% (up) |
| Previous Close | USD 8.72 |
| Open | USD 8.99 |
| Day Range | USD 8.73 – 9.37 |
| 52-Week Range | USD 2.88 – 18.2 |
| Volume | 14,049 shares |
| Market Cap | $21.19M |
| Exchange | NCM |
Technical Analysis (PLRZ)
Nexqual's technical model rates PLRZ "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 07:41 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.73 (neutral) |
| vs SMA50 | Below (USD 10.69) |
| MACD | -0.48 (negative) |
Analyst Ratings (PLRZ)
Wall Street analysts rate PLRZ "None", per Nexqual as of October 24, 2026 at 07:41 UTC.
| Consensus Rating | None |
|---|
Earnings (PLRZ)
Source: Nexqual, October 24, 2026 at 07:41 UTC.
Financials & Fundamentals (PLRZ)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -21.42% |
| Current Ratio | 36.37 |
| Total Cash | $16.07M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 07:41 UTC.
Financial Health Score (PLRZ)
Nexqual rates Polyrizon Ltd.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 07:41 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% (last 12 months) |
| Balance Sheet | Mixed — $16M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M (TTM) |
| Efficiency | Critical — ROE -21%, ROA -23.3% |
Ownership (PLRZ)
| Insider Ownership | +0.76% |
|---|---|
| Institutional Ownership | +9.35% |
| Shares Outstanding | 2.43M |
| Float | 1.87M |
| Short % of Float | +2.12% |
Source: Nexqual, October 24, 2026 at 07:41 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVNIF | Nvni Group Limited | USD 0.07 | ▲ 14.75% |
| TGL | Treasure Global Inc. | USD 0.22 | ▼ 6.54% |
| KIDZ | KIDZ AI Inc. | USD 1.67 | ▲ 1.21% |
| SMX | SMX (Security Matters) Public L | USD 1.75 | ▼ 4.37% |
| NIVF | NewGenIvf Group Limited | USD 1.46 | ▲ 22.48% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 07:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt